A Common Pathogenic Mechanism Linking Type-2 Diabetes and Alzheimer’s Disease: Evidence from Animal Models
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The failure of large-scale drug trials targeting the amyloidogenic pathway in Alzheimer’s disease (AD) is increasing the need to identify a novel pathogenic mechanism. Studies finding a relationship between sporadic AD and type-2 diabetes mellitus (T2DM) are now receiving more attention. The risk for developing both T2DM and sporadic AD increases exponentially with age, and having T2DM doubles the risk of developing AD. The postmortem brains of AD patients show altered activities of insulin receptors and downstream molecules, as well as reduced protein and mRNA levels of insulin. More-recent laboratory research using animal models has identified mechanisms that are shared by diabetes and AD. Exogenous application of streptozotocin, which disrupts systemic insulin secretion, results in insulin deficiency, increased tau phosphorylation,and cognitive impairments that can be reversed by exogenous insulin supplementation. However, AD pathology is more severe in T2DM animal models exhibiting hyperinsulinemia and insulin resistance, and this is not modulated by insulin. The symptoms of this AD pathology included increased tau phosphorylation at multiple sites, increased tau cleavage, and greater neuronal and synaptic damage, even with increased amyloid β protein production. It has therefore been suggested that hyperinsulinemia and insulin resistance represent major factors underlying AD in T2DM. A recent study involving cross-mating ob/ob and amyloid precursor protein transgenic mice provided evidence that T2DM and AD aggravate each other, and suggested that cerebral vessels constitute an important substrate that is commonly damaged by the two major disorders. Given the evidence provided by animal models, further investigation of the mechanisms underlying T2DM in AD should help to identify potential treatment targets in AD.
Abstract
The failure of large-scale drug trials targeting the amyloidogenic pathway in Alzheimer’s disease (AD) is increasing the need to identify a novel pathogenic mechanism. Studies finding a relationship between sporadic AD and type-2 diabetes mellitus (T2DM) are now receiving more attention. The risk for developing both T2DM and sporadic AD increases exponentially with age, and having T2DM doubles the risk of developing AD. The postmortem brains of AD patients show altered activities of insulin receptors and downstream molecules, as well as reduced protein and mRNA levels of insulin. More-recent laboratory research using animal models has identified mechanisms that are shared by diabetes and AD. Exogenous application of streptozotocin, which disrupts systemic insulin secretion, results in insulin deficiency, increased tau phosphorylation,and cognitive impairments that can be reversed by exogenous insulin supplementation. However, AD pathology is more severe in T2DM animal models exhibiting hyperinsulinemia and insulin resistance, and this is not modulated by insulin. The symptoms of this AD pathology included increased tau phosphorylation at multiple sites, increased tau cleavage, and greater neuronal and synaptic damage, even with increased amyloid β protein production. It has therefore been suggested that hyperinsulinemia and insulin resistance represent major factors underlying AD in T2DM. A recent study involving cross-mating ob/ob and amyloid precursor protein transgenic mice provided evidence that T2DM and AD aggravate each other, and suggested that cerebral vessels constitute an important substrate that is commonly damaged by the two major disorders. Given the evidence provided by animal models, further investigation of the mechanisms underlying T2DM in AD should help to identify potential treatment targets in AD.
참고문헌 (63)
- Suh GH, "economic costs of dementia in Korea, 2002", Int J Geriatr Psychiatry, 21, pp.722~728 (2006)
- Hardy J, "The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics", Science, 297, pp.353~356 (2002)
- Rafii MS, "Recent developments in Alzheimer’s disease therapeutics", BMC Med, 7, pp.7~ (2009)
- Mangialasche F, "Alzheimer’s disease: clinical trials and drug development", Lancet Neurol, 9, pp.702~716 (2010)
- Leibson CL, "Risk of dementia among persons with diabetes mellitus: a population-based cohort study", Am J Epidemiol, 145, pp.301~308 (1997)
- Ott A, "Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study", Neurology, 53, pp.1937~1942 (1999)
- Grodstein F, "Nurses’ Health Study. Type 2 diabetes and cognitive function in community-dwelling elderly women", Diabetes Care, 24, pp.1060~1065 (2001)
- Peila R, "Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study", Diabetes, 51, pp.1256~1262 (2002)
- Arvanitakis Z, "Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function", Arch Neurol, 61, pp.661~666 (2004)
- Xu WL, "Fratiglioni L. Diabetes mellitus and risk of dementia In the Kungsholmen project: a 6-year follow-up study", Neurology, 63, pp.1181~1186 (2004)
- Craft S, "Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype", Neurology, 50, pp.164~168 (1998)
- Rivera EJ, "Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine", J Alzheimers Dis, 8, pp.247~268 (2005)
- Szkudelski T, "The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas", Physiol Res, 50, pp.537~546 (2001)
- Kim B, "Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes", Endocrinology, 140, pp.5294~5301 (2009)
- Planel E, "Insulin dysfunction induces in vivo tau hyperphosphorylation through distinct mechanisms", J Neurosci, 27, pp.13635~13648 (2007)
- Jolivalt CG, "Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer’s disease and correction by insulin", J Neurosci Res, 86, pp.3265~3274 (2008)
- Brant AM, "Immunological analysis of glucose transporters expressed in different regions of the rat brain and central nervous system", Biochem Biophys Res Commun, 192, pp.1297~1302 (1993)
- Salkovic-Petrisic M, "Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signall-ing pathway", J Neurochem, 96, pp.1005~1015 (2006)
- Deng Y, "Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer’s disease", Am J Pathol, 175, pp.2089~2098 (2009)
- Steen E, "Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease--is this type 3 diabetes", J Alzheimers Dis, 7, pp.63~80 (2005)
- Li ZG, "Alzheimer-like changes in rat models of spontaneous diabetes", Diabetes, 56, pp.1817~1824 (2007)
- de Calignon A, "Caspase activation precedes and leads to tangles", Nature, 464, pp.1201~1204 (2010)
- Janson J, "Increased risk of type 2 diabetes in Alzheimer disease", Diabetes, 53, pp.474~481 (2004)
- Schubert M, "Role for neuronal insulin resistance in neurodegenerative diseases", Proc Natl Acad Sci U S A, 101, pp.3100~3105 (2004)
- Schubert M, "Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation", J Neurosci, 23, pp.7084~7092 (2003)
- Killick R, "Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice", Biochem Biophys Res Commun, 386, pp.257~262 (2009)
- Farris W, "Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo", Proc Natl Acad Sci U S A, 100, pp.4162~4167 (2003)
- Sudoh S, "Differential effects of proteases invol-ved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells", Biochemistry, 41, pp.1091~1099 (2002)
- Ke YD, "Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer’s disease", PLoS One, 4, pp.7917~ (2009)
- Li Y, "GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease", J Alzheimers Dis, 19, pp.1205~1219 (2010)
- Plaschke K, "Insulin-resistant brain state after intracerebroventricular streptozotocin injection exacerbates Alzheimer-like changes in Tg2576 AbetaPP-overexpressing mice", J Alzheimers Dis, 19, pp.671~704 (2010)
- Ho L, "Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease", FASEB J, 18, pp.902~904 (2004)
- Kohjima M, "Increased food intake leads to obesity and insulin resistance in the tg2576 Alzheimer’s disease mouse model", Endocrinology, 151, pp.1532~1540 (2010)
- Julien C, "High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model", Neurobiol Aging, 31, pp.1516~1531 (2010)
- Takeda S, "Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes", Proc Natl Acad Sci U S A, 107, pp.7036~7041 (2010)
- Ueda H, "Age-dependent changes in phenotypes and candidate gene analysis in a polygenic animal model of Type II diabetes mellitus; NSY mouse", Diabetologia, 43, pp.932~938 (2000)
- Yan SD, "RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease", Nature, 382, pp.685~691 (1996)
- Townsend M, "Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway", J Biol Chem, 282, pp.33305~33312 (2007)
- Lee HK, "The insulin", Akt signaling pathway is targeted by intracellular beta-amyloid, 2009, pp.20, 1533~1544
- Zhao WQ, "Amyloid beta oligomers induce impairment of neuronal insulin receptors", FASEB J, 22, pp.246~260 (2008)
- De Felice FG, "Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers", Proc Natl Acad Sci U S A, 106, pp.1971~1976 (2009)
- Phiel CJ, "GSK-3alpha regulates production of Alzheimer’s disease amyloid-beta peptides", Nature, 423, pp.435~439 (2003)
- Hooper C, "The GSK3 hypothesis of Alzheimer’s disease", J Neurochem, 104, pp.1433~1439 (2008)
- Zhao WQ, "Role of insulin and insulin receptor in learning and memory", Mol Cell Endocrinol, 177, pp.125~134 (2001)
- Craft S, "Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype", Neurology, 50, pp.164~168 (1998)
- Watson GS, "Insulin increases CSF Abeta42 levels in normal older adults", Neurology, 60, pp.1899~1903 (2003)
- Leissring MA, "En-hanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death", Neuron, 40, pp.1087~1093 (2003)
- Cook DG, "Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer’s disease is associated with the apolipoprotein E-epsilon4 allele", Am J Pathol, 162, pp.313~319 (2003)
- Rachel Mistur, "Current Challenges for the Early Detection of Alzheimer’s Disease: Brain Imaging and CSF Studies", Journal of Clinical Neurology, 5(4), pp.153~166 (2009), 대한신경과학회
- Liu F, "Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease", Brain, 132, pp.1820~1832 (2009)
- Brownlee M, "Advanced protein glycosylation in diabetes and aging", Annu Rev Med, 46, pp.223~234 (1995)
- Vitek MP, "Advanced glycation end products contribute to amyloidosis in Alzheimer disease", Proc Natl Acad Sci U S A, 91, pp.4766~4770 (1994)
- Necula M, "Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro", J Biol Chem, 279, pp.49694~49703 (2004)
- Fishel MA, "Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults", Arch Neurol, 62, pp.1539~1544 (2005)
- Wyss-Coray T, "Inflammation in Alzheimer disease: driving force, bystander or beneficial response", Nat Med, 12, pp.1005~1015 (2006)
- Desrocher M, "Neurocognitive correlates of type 1 diabetes mellitus in childhood", Child Neuropsychol, 10, pp.36~52 (2004)
- Lee ZS, "Plasma insulin, growth hormone, cortisol, and central obesity among young Chinese type 2 diabetic patients", Diabetes Care, 22, pp.1450~1457 (1999)
- Lupien S, "Basal cortisol levels and cognitive deficits in human aging", J Neurosci, 14, pp.2893~2903 (1994)
- Stranahan AM, "Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons", Nat Neurosci, 11, pp.309~317 (2008)
- Csernansky JG, "Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia", Am J Psychiatry, 163, pp.2164~2169 (2006)
- Huang CW, "Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer’s disease", J Clin Neurosci, 16, pp.1283~1286 (2009)
- Schmidt R, "Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study", Diabetes, 53, pp.687~692 (2004)
- Esiri MM, "Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease", Lancet, 354, pp.919~920 (1999)